HSBC Holdings plc set a GBX 4,100 ($53.39) price target on AstraZeneca plc (LON:AZN) in a research note issued to investors on Tuesday. The firm currently has a sell rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently issued reports on AZN. Shore Capital reaffirmed a hold rating on shares of AstraZeneca plc in a research note on Wednesday, June 21st. Deutsche Bank AG decreased their target price on shares of AstraZeneca plc from GBX 5,700 ($74.23) to GBX 5,300 ($69.02) and set a buy rating for the company in a report on Thursday, August 3rd. Liberum Capital reiterated a buy rating and issued a GBX 5,500 ($71.62) target price on shares of AstraZeneca plc in a report on Monday, June 5th. Credit Suisse Group reiterated a neutral rating and issued a GBX 5,000 ($65.11) target price on shares of AstraZeneca plc in a report on Monday, June 19th. Finally, J P Morgan Chase & Co reiterated a neutral rating on shares of AstraZeneca plc in a report on Thursday, May 11th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of GBX 4,932.67 ($64.24).

AstraZeneca plc (LON:AZN) opened at 4384.00 on Tuesday. The firm’s 50-day moving average is GBX 4,929.68 and its 200 day moving average is GBX 4,859.79. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The firm’s market capitalization is GBX 55.50 billion.

COPYRIGHT VIOLATION NOTICE: “AstraZeneca plc (AZN) PT Set at GBX 4,100 by HSBC Holdings plc” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/12/astrazeneca-plc-azn-pt-set-at-gbx-4100-by-hsbc-holdings-plc.html.

The company also recently declared a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be given a GBX 68.90 ($0.90) dividend. This represents a dividend yield of 1.35%. The ex-dividend date is Thursday, August 10th.

In other news, insider Nazneen Rahman purchased 39 shares of the company’s stock in a transaction dated Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($56.91) per share, with a total value of £1,704.30 ($2,219.43).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.